Long-Term Effectiveness and Safety of Denosumab for Osteoporosis in Patients With Rheumatic Diseases
Authors' conclusion
The present study suggests that the long-term use of denosumab is an effective and generally safe option for increasing BMD in patients with RDs.
Study context
- Population
- Patients with rheumatic diseases receiving denosumab for osteoporosis (OP) (median age 66.5 years, 92.1% female, 68.5% receiving glucocorticoid (GC) therapy)
- Participants
- 165 patients
- Outcome
- BMD at the lumbar spine (up to 7 years) and femur (up to 3 years)
- Follow-up
- Up to 7 years
Methodological detailssingle-group
- Single-group
Main finding
As reported in the abstract
Lumbar spine BMD
- Lumbar spine bone mineral density (BMD) significantly increased over 7 years
- P < 0.001
Observational data: associations, not effects.
Further findings
| Outcome | Values |
|---|---|
| Retention rate of denosumab · up to 7 years | Denosumab 68.1% |
Femoral neck, trochanter and total hip BMD · up to 3 years
- Femoral neck, trochanter and total hip BMD significantly increased for up to 3 years
- P < 0.001
Lumbar spine BMD by GC dose, age, renal dysfunction (subgroups)
- Lumbar spine BMD significantly increased regardless of GC dose, age, or renal dysfunction
Safety
| Outcome | Values |
|---|---|
| Osteonecrosis of the jaw · during treatment | Denosumab 2 events |
| New fractures · during treatment | Denosumab 10 events |
Serious adverse events
- The most common serious adverse event was infection
Original publication
Long-Term Effectiveness and Safety of Denosumab for Osteoporosis in Patients With Rheumatic Diseases. J Rheumatol. Published 1 June 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →